Vincent Medical Holdings Limited (1612) AI Stock Analysis

• Market Cap: HK$267.87M
• Dividend Yield: 7.56%
• Average Volume (3M): 436.33K
• Price to Earnings (P/E): 3.8
• Beta (1Y): 0.40
• Revenue Growth: 11.56%
• EPS Growth: 20.29%
• Country: HK
• Employees: 1,328
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Devices
• EPS (TTM): 0.06
• Shares Outstanding: 653,336,300
• 10 Day Avg. Volume: 220,000
• 30 Day Avg. Volume: 436,333
• PEG Ratio: 0.35
• Price to Book (P/B): 0.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 19.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Vincent Medical Holdings Limited garners a favorable overall score due to its strong financial foundation characterized by significant revenue growth and a solid balance sheet. Despite challenges in cash flow management and income volatility, the company's low P/E ratio and high dividend yield offer attractive valuation prospects. However, technical analysis signals a bearish trend, suggesting caution for potential investors.

Vincent Medical Holdings Limited Business Overview & Revenue Model

Company Description

Vincent Medical Holdings Limited (1612) is a company engaged in the design, development, manufacturing, and distribution of a comprehensive range of medical devices. Operating primarily in the healthcare sector, the company offers products such as respiratory care devices, imaging disposable products, and other medical disposables that are crucial for hospitals and healthcare providers in delivering patient care.

How the Company Makes Money

Vincent Medical Holdings Limited generates revenue through the sale of its medical products, which are distributed to hospitals, clinics, and healthcare facilities around the world. The company's key revenue streams include its respiratory care devices and imaging disposable products, which are essential in various medical procedures. Vincent Medical leverages a combination of direct sales and distribution partnerships to ensure its products reach a wide customer base. Additionally, the company may engage in research and development collaborations to innovate and enhance its product offerings, contributing further to its revenue growth.

Vincent Medical Holdings Limited Financial Statement Overview

Summary

Vincent Medical Holdings Limited shows strong revenue growth and solid equity positioning, reflective of its potential in the medical devices industry. However, cash flow management and income volatility remain areas for improvement. Despite these challenges, the company's low leverage and improving profitability metrics suggest a stable financial foundation with room for growth.

Income Statement

Vincent Medical Holdings Limited demonstrated a positive revenue growth rate of approximately 11.56% for 2024 compared to 2023. The gross profit margin for 2024 was approximately 32.48%, indicating healthy profitability, although the net profit margin was lower at about 8.64%. The EBIT margin was approximately 9.95%, and the EBITDA margin was 12.49%, showing reasonable operational efficiency. However, past fluctuations in EBIT and net income suggest some volatility.

Balance Sheet

The company maintains a solid equity base with an equity ratio of approximately 62.93% in 2024. The debt-to-equity ratio is relatively low at about 0.17, suggesting a conservative leverage approach. Return on equity improved to approximately 11.95% in 2024, indicating good returns on shareholder investment, although past years showed significant swings.

Cash Flow

The company's free cash flow was positive in 2023 but declined to zero in 2024, indicating potential challenges in cash generation. The operating cash flow to net income ratio was zero in 2024, highlighting a need for improvement in converting income to cash. Historical free cash flow growth was volatile, reflecting the need for better cash flow management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
800.96M	717.97M	629.24M	777.72M	1.16B
	Gross Profit
259.99M	222.59M	147.83M	243.83M	478.79M
	EBIT
79.67M	65.78M	-7.50M	79.46M	297.15M
	EBITDA
100.00M	104.43M	28.29M	119.52M	334.17M
	Net Income Common Stockholders
69.17M	57.27M	-17.40M	60.70M	216.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
173.44M	175.78M	159.34M	173.17M	169.07M
	Total Assets
919.68M	786.61M	726.70M	846.15M	946.87M
	Total Debt
99.65M	37.38M	60.39M	62.96M	84.69M
	Net Debt
-73.79M	-138.40M	-98.95M	-110.21M	-84.38M
	Total Liabilities
336.33M	243.52M	228.09M	245.72M	341.69M
	Stockholders Equity
578.55M	541.84M	498.01M	598.36M	611.56M
Cash Flow		Free Cash Flow
0.00	61.28M	57.67M	94.48M	142.19M
	Operating Cash Flow
0.00	124.97M	76.27M	119.43M	204.77M
	Investing Cash Flow
0.00	-62.37M	-18.61M	-20.69M	-132.19M
	Financing Cash Flow
0.00	-45.37M	-67.84M	-101.16M	10.13M

Vincent Medical Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1612, the sentiment is Negative. The current price of 0.41 is above the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.41, and above the 200-day MA of 0.41, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1612.

Vincent Medical Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1061	78 Outperform	HK$2.42B	7.87	15.18%	2.46%	-2.15%	12.09%
1513	74 Outperform	$30.95B	10.58	14.56%	5.63%	-5.37%	6.28%
1066	74 Outperform	$27.54B	12.34	8.95%	3.34%	-3.09%	0.67%
1612	69 Neutral	HK$267.87M	3.81	12.35%	7.56%	11.56%	20.29%
2196	65 Neutral	$61.75B	12.52	6.22%	1.97%	-2.82%	11.93%
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%

Vincent Medical Holdings Limited Corporate Events

Vincent Medical Holdings Announces 2025 AGM and Key Resolutions

Vincent Medical Holdings Limited has announced its annual general meeting scheduled for May 21, 2025, in Hong Kong. Key agenda items include the adoption of financial statements for 2024, approval of a final dividend, re-election of directors, and authorization for the board to manage share allotments. The resolutions aim to strengthen the company’s governance and financial strategies, potentially impacting shareholder value and market positioning.

Vincent Medical Holdings Announces EGM for Key Approvals

Vincent Medical Holdings Limited has announced an Extraordinary General Meeting (EGM) scheduled for May 21, 2025, to approve the Healthcare and Wellness Products Purchase Agreement and the Proposed Annual Caps. This meeting is significant for stakeholders as it involves ratifying key agreements that could impact the company’s operational strategies and market positioning.

Vincent Medical Holdings Delays Circular Dispatch for Healthcare Agreement

Vincent Medical Holdings Limited announced a delay in the dispatch of a circular related to its Healthcare and Wellness Products Purchase Agreement. Originally scheduled for release by April 10, 2025, the circular will now be dispatched by April 30, 2025, due to additional time needed to finalize the included information. This delay may impact stakeholders awaiting further details on the agreement and its proposed annual caps.

Vincent Medical Holdings Reports Strong 2024 Financial Performance and Dividend Increase

Vincent Medical Holdings Limited reported an 11.6% increase in revenue for the year ended December 31, 2024, reaching HK$801.0 million, with a significant 37.7% growth in the imaging disposable products segment. The company’s profit rose by 21.8% to HK$70.9 million, and it declared a final dividend of HK1.7 cents per share. The company has implemented efficiency enhancements and maintained a focus on quality and compliance, obtaining EU MDR certification for its quality management system.

Vincent Medical Holdings Announces Final Dividend for 2024

Vincent Medical Holdings Limited announced a final ordinary cash dividend of HKD 0.017 per share for the financial year ending December 31, 2024. This announcement reflects the company’s financial performance and commitment to returning value to shareholders, with the payment date set for June 20, 2025.

Vincent Medical Enters New Healthcare Products Agreement

Vincent Medical Holdings Limited announced that its subsidiary, VME, has entered into a Healthcare and Wellness Products Purchase Agreement with VRDG, a connected person under the company’s controlling shareholder, VRI. This agreement, effective from March 19, 2025, to December 31, 2027, involves the supply of healthcare and wellness products. The transactions under this agreement, when aggregated with those under a previous agreement, exceed the 5% threshold, necessitating compliance with reporting and approval requirements under the Listing Rules.

Vincent Medical Holdings to Review Annual Financial Results

Vincent Medical Holdings Limited has announced that its board of directors will convene on March 19, 2025, to review and approve the company’s annual financial results for the year ending December 31, 2024. The meeting will also address the potential declaration of a final dividend, which could impact the company’s financial strategy and shareholder returns.